BioCentury
ARTICLE | Clinical News

Calithera gains on Phase I leukemia data

May 22, 2015 1:15 AM UTC

Calithera Biosciences Inc. (NASDAQ:CALA) rose $1.17 (11%) to $12.02 on Thursday after it said one patient had a complete response among 15 efficacy-evaluable patients in a Phase I trial of CB-839 to treat relapsed or refractory acute myelogenous leukemia (AML). The company expects data from the study to be presented next month at the European Hematology Association meeting in Vienna.

Calithera said the patient showed a CR in the bone marrow with incomplete recovery of peripheral counts after six treatment cycles of 21 days each. Patients in the study received doses of 100-1,000 mg three times daily. ...